With emphasis on the global markets, Jeff uses key positioning and strategies to identify investment vehicles that meet the Investment Advisor’s proprietary investment parameters. He currently serves as the Managing Partner of International Infusion, a think tank venture capital firm aimed directly at disruptive technologies. Jeff is active in identifying various companies for an acquisition and for developing post acquisition exit strategies, typically involving a public offering.

Other Notable Achievements:

• Co-founder and Managing Member of the General Partner and the Investment Advisor.
• Co-founder and Director of Camp Athlete, Inc., a non-profit organization helping students improve their academic and athletic achievements.
• Graduated from the University of Southern Indiana with a B.S. in Psychology.

Scott has been instrumental in the development and expansion of International Infusion’s current portfolio, leveraging key business development relationships, both domestic and international. He has managed the firm’s research committee, focusing on vetting potential projects across an array of sectors. Scott serves as the Chair of the Global Development division of International Infusion and is responsible for all activities related to finance, accounting, and manages all activities with the back office, administrators, and corporate communication.

Other Notable Achievements:

• Co-founder and Managing Member of the General Partner and the Investment Advisor.
• Co-founder and Director of Camp Athlete, and is also a Director and Secretary of the Sadanah Foundation Graduated from University of Illinois at Chicago with a B.S. in Business Marketing and an M.B.A. with a concentration in Real Estate.

An accomplished global business veteran of more than 40 years Mr. Chan Heng Fai specializes in financial restructuring and corporate transformation to unlock value and unleash entrepreneurial zeal while managing risk. He has successfully restructured more than 35 corporations in different industries and countries. Some of the remarkable companies that he has built, rescued or transformed include American Pacific Bank (USA), China Gas Holdings Limited and Heng Fai Enterprises Limited both (listed on The Stock Exchange of Hong Kong), Global Med Technologies, Inc. (U.S. medical software company exited for US$60 million), Singhaiyi Group Ltd (listed on the Singapore Exchange). More details of his achievements and track record can be found at http://fai185.com/ or by clicking here for a full length profile.

Dr. Mahvi is a leading health care system executive and surgeon with experience in building a high-quality ambulatory health-care delivery system with novel delivery models, a national speaker on health care systems design, and an expert in creating a culture of physician leadership. He has 25+ years of progressive leadership roles in academic medicine, has created joint educational programs for engineers and medical students, is an inventor, investor and advisor of three start-up companies, and has been a member of numerous professional boards. At Northwestern, he was Professor of Surgery and Chief, Division of Gastrointestinal and Oncologic Surgery. He also served as President of the Northwestern University’s Medical Group, integrating a community based primary care group into a $900M specialty-based academic physician group with improved patient engagement and access to care – while transitioning a budget deficit to a budget surplus. Before, Dr. Mahvi served for 19 years on the faculty of the University of Wisconsin-Madison as Chief of Surgical Oncology and Director of the General Surgery Residency Program, and led a continuously-funded research lab in collaboration with the University’s School of Engineering. During his tenure as Chair of the American Board of Surgery (2014 – 2015), he developed national policy on the education and management of the surgical workforce. Dr. Mahvi completed his undergraduate work at the University of Oklahoma, earned an MD at the Medical University of South Carolina, served his residency and completed a research fellowship in immunology at Duke University Medical Center. His research has focused on developing new biomedical devices in treating liver cancer (he is a national/international authority on hepatobiliary cancer) and has developed, manufactured, and performed clinical trials of novel biologics. He has authored 100+ peer reviewed research articles, and presented nationally/ internationally on cancer-related topics.

Dr. Seperack has spent the last 32 years as a biopharmaceutical researcher and as a Biotech patent attorney. As a Post-Doctoral Fellow Dr. Seperack discovered the molecular mechanism of a murine coat color mutation which was a novel member of the non-muscle myosin gene family. As a scientist at Bayer, Dr. Seperack developed models to screen compounds to treat osteoarthritis. Following his scientific career, Dr. Seperack became a patent attorney, and in the law firm environment, prosecuted patents directed to numerous biotech applications. As In-House counsel, Dr. Seperack drafted applications that resulted in a corporate acquisition, and managed a patent department that was prosecuting chemical and biological patent applications. Dr. Seperack managed small molecule portfolios while drafting and prosecuting biological applications. He received his PhD from SUNY Stony Brook, and his JD from Golden Gate University.

Brian E. Harvey, MD, PhD is a physician and biochemist with academic research, clinical practice, U.S. FDA regulatory, bio-pharmaceutical industry and non-profit experience. He currently is Principal Consultant at Brian E Harvey LLC providing regulatory advice for biologics, drugs and medical device development programs. In addition, he volunteers as the Executive Vice President, Science and Regulatory at the non-profit Global Liver Institute (www.globalliver.org) based in Washington, DC. Prior to his current activities, Dr. Harvey held positions as Vice President of U.S. Regulatory Strategy at Pfizer and Vice President of U.S. Regulatory Policy at Sanofi-Aventis, including during the period of the Genzyme merger. Dr. Harvey also held several senior roles at FDA, serving in the medical device (CDRH), biologic (CBER) and drug (CDER) Center from 1995 to 2007. As Director of CDER Division of Gastroenterology Products Office of New Drugs (OND), he headed the regulatory review teams for NDA and BLA submissions and chaired FDA meetings with regulated industry on a regular basis. As Director, he created the Inborn Errors of Metabolism Team within the GI division to focus on rare disease product approvals. Prior to this, he served as Deputy Director for the Office of Drug Evaluation 5 (CDER) and CBER Associate Director for Policy, Office of Therapeutics Research and Review (OTRR). Brian graduated with honors from Middlebury College in Vermont. After college, he received his PhD in biochemistry, followed by his MD at the University of Connecticut. In his last year of medical school, he began post-doctoral research on colorectal cancer and the role of sialic acid in site-specific metastasis at Harvard University. He completed his internship and residency in internal medicine at Harvard’s Beth Israel Hospital, which included clinical rotations at Dana-Farber Cancer Institute, West Roxbury Veterans Hospital, clinical research at Brigham and Women’s Hospital and the Harvard School of Public Health. His bench research activities resulted in several publications in peer reviewed journals. This was followed by a three year gastroenterology fellowship at Johns Hopkins Hospital, Baltimore, MD, which included hepatology training and being a member of the Liver Transplant Service.

Ms. Runk has more than 35 years of experience in research, including all phases of pre-clinical and clinical drug development. Her research and efforts have been instrumental in the biopharmaceutical industry while working for Oread, ILEX Oncology, PSI and Ergomed. Ms. Runk was a key leader in impacting oncology therapeutics research due to her recommendations based on in-depth analysis at CytRx Corporation. She holds a B.S. in Biology and a B.A. in Psychology from SUNY Albany and an M.B.A. from University of Phoenix.

Mr. Rubinfeld has more than 22 years of experience in drug development, site initiation, site management, and contract negotiations. He has spent many years establishing close personal relationships with many of the KOLs in Oncology and Hematology while working for SuperGen, Pharmatech, and TS BioPharma. Mr. Rubinfeld’s extensive experience includes spearheading and managing more than 60 clinical trials. He holds a B.A. degree in Political Science and Psychology from San Jose State University. He also earned a Master’s in Social Work from San Jose State University. Mr. Rubinfeld is a member of American Society of Clinical Oncology (ASCO).

Dr. Brownell serves as Executive Vice President of Operations and Project Management for the various biopharmaceutical companies in the current portfolio where she oversees all development programs across a diverse therapeutic and diagnostic platform. She has spent the last 35 years in the bio/pharmaceutical arena where she has played key roles in Discovery, Development and Opportunity Assessment to drive innovation.

Other Notable Achievements:

• Founding team member of Aerovance, Inc. which garnered over $60 MUSD, completed six clinical trials in 3.5 years, and built a right-sized matrixed organization
• Co-founder of ZephyrBiotech, LLC, a consulting practice that provides services to entrepreneurial life science companies
• Graduated from Yale University with a PhD in Biology

Dr. Swaroop is an Associate Professor of Surgery in the Division of Trauma and Critical Care Surgery and is on the faculty of the Center for Global Health in the Institute for Public Health and Medicine at Northwestern University’s Feinberg School of Medicine. She has served or serves on multiple national and international leadership boards. She is Founder and Executive Director of the Northwestern Trauma and Surgical Initiative, her Global Surgery Lab. Additionally, Dr. Swaroop runs an international team in projects ranging from helmet usage to the development of a trauma system for the department of Santa Cruz, Bolivia.

Other Notable Achievements:

• Author of 30+ peer reviewed research articles, and has presented internationally on Trauma and Global Surgery topics.
• President and Founder of the Sadanah Foundation, a not for profit entity that aims to build sustainable access to healthcare and education in low resource settings.
• Completed her General Surgery residency at the University of South Florida and her Surgical Critical Care Fellowship at Northwestern.

Ms. Su has 25 years experience in investment banking, management consulting, corporate valuation, financial due diligence and accounting across the globe. She has led multiple M&A transactions on behalf of buyers and sellers as well as valuation in various industries including manufacturing and distribution, automotive, financial services, healthcare, consumer products, food, technology, retail and real estate. Her clients range from Chinese state-owned enterprises, Fortune 500 companies, private equity and privately-owned businesses in both the U.S. and China. With deep cultural understandings and native language skills of the U.S. and China, Ms. Su helps Chinese and U.S. companies make overseas investments through cross-border mergers and acquisitions, joint ventures and greenfield investments. Ms. Su co-founded Centauri Capital Partners, LLC, a cross-border M&A advisor and business broker, focusing on helping Chinese investors expand overseas. Her previous experience includes capital planning and M&A at IBD of a Big Four accounting firm and a US-listed insurance company, head of China practice of a mid-sized global accounting firm, and partner and CFO of small and medium enterprises. Ms. Su has presented many times on cross-border M&A, corporate valuation, cross-border transactions and cross-cultural business management, as well as published articles on related topics. Ms. Su earned her MBA and MA from the University of Illinois at Chicago with concentrations in Finance and Economics. Her undergraduate degree is a BS in International Finance from Renmin University of China. She is a CPA, Accredited in Business Valuation, and Chartered Financial Consultant.

Mr. Mei is a trusted business and legal advisor to private funds and strategic acquirers engaging in cross-border M&A transactions with a focus on Chinese companies and private funds investing in the United States. Mr. Mei has advised over 30 cross-border M&A transactions totaling more than $11 billion in aggregate value. After obtaining his B.S.E.E. and J.D. from the University of Michigan, Mr. Mei worked for the international law firm Sullivan & Cromwell, Morrison & Foerster and DLA Piper as senior lawyer. He is a New York State registered lawyer and is one of the top 500 recommended lawyer in private equity and M&A field in 2015. Mr. Mei is also a partner at a Chicago-based M&A law firm. Mr. Mei was a member of the American Institute of Electrical and Electronics Engineers and worked as an engineer at General Motors Global Headquarters. He also served as an engineer at IBM chip R&D center with solid industrial knowledge. Mr. Mei has been involved in a number of landmark cross-border M&A transactions in the areas of Fintech, IT, semiconductors and industrials, including Ping An’s investment in R3 blockchain consortium, Tsinghua Unigroup’s take private of Xueda, Tsinghua Unigroup’s take private of Spreadtrum, Focus Media’s take private, corporate divestures to Hengst SE & Co by Perma-Pipe International and INEOS Group’s acquisition of Calabrian, among many others. Mr. Mei has also worked on the initial public offerings of China Pacific Insurance, AIA and Shanghai Pharmaceuticals. Mr. Mei co-founded Centauri Capital Partners, LLC, a cross-border M&A advisor and business broker, focusing on helping Chinese investors expand overseas. Mr. Mei has maintained close relationships with strategic players and financial sponsors, as well as a number of top-tier high-technology parks in China, with extensive contacts both in China and the United States.